Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » ACOR Rocket!

 - UBBFriend: Email this page to someone!    
Author Topic: ACOR Rocket!
kXsToCkKiD
Member


Rate Member
Icon 8 posted      Profile for kXsToCkKiD     Send New Private Message       Edit/Delete Post   Reply With Quote 
Acor blasted up after a ms treatment. Yesterday up almost 300% and now today 30%. Wish i woulda bought in instead of just watching to see what it would do...

--------------------
There are 10 types of people in this world, those who can read binary, and those who cannot.

Posts: 49 | From: Milwaukee, Wisconsin | Registered: Sep 2006  |  IP: Logged | Report this post to a Moderator
invester
Member


Icon 1 posted      Profile for invester     Send New Private Message       Edit/Delete Post   Reply With Quote 
The next ACOR is ACTC.
Posts: 4381 | From: houston | Registered: Mar 2006  |  IP: Logged | Report this post to a Moderator
wadeinni
Member


Member Rated:
4
Icon 1 posted      Profile for wadeinni     Send New Private Message       Edit/Delete Post   Reply With Quote 
AP
Ahead of the Bell: Acorda Therapeutics
Friday September 29, 8:50 am ET
Acorda Therapeutics Rises in Pre-Market After Surging All Week on MS Drug Trial Data

NEW YORK (AP) -- Shares of Acorda Therapeutics Inc., which have quadrupled this week on positive data on the company's multiple sclerosis treatment, rose sharply in Friday pre-market trading, helped by a PiperJaffray upgrade.

ADVERTISEMENT
click here
Shares rose $1.65 cents, or almost 19.1 percent, to $10.30 on the INET electronic exchange, after closing at $8.65 Thursday on the Nasdaq. The stock has traded between $2.20 to $11.90 since it went public at $6.17 on Feb. 10.

The biotech stock nearly tripled Monday and continued its surge Tuesday to set a new 52-week high. Acorda said Monday its multiple sclerosis treatment successfully improved patients' walking ability in a late-stage clinical trial.

Analyst Caroline Y. Stewart upgraded the stock to "Outperform" from "Marketperform" and lifted her target price to $14 from $6.50.

In a note to clients, she said she expects the new drug, called Fampridine-SR, will need additional testing, which could take a year. But she said doctors have indicated they want to try the drug in a broad MS patient population, not just in patients with walking disabilities.

Stewart forecasts total peak market opportunity for Fampridine-SR of $300 million.

--------------------
One risk I enjoy: daytrading stocks

Posts: 273 | From: New York City | Registered: Sep 2004  |  IP: Logged | Report this post to a Moderator
Lootcifer
Member


Member Rated:
4
Icon 1 posted      Profile for Lootcifer     Send New Private Message       Edit/Delete Post   Reply With Quote 
Nice bounce from the bottom we have here today. The analysts upgrade and all the exposure in the media is proving to be quite a fuel for the stock. The rest of the week will catch this at a new high, IMO. The momo has not left the stock and will not for a while.

--------------------
Best Regards and Good Trading

Posts: 239 | From: Florida City, FL | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
Lootcifer
Member


Member Rated:
4
Icon 1 posted      Profile for Lootcifer     Send New Private Message       Edit/Delete Post   Reply With Quote 
What a finish folks, I told you this was coming. There's just too much momo in this right now. End of week will be spectacular

--------------------
Best Regards and Good Trading

Posts: 239 | From: Florida City, FL | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share